Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (NCT05478538) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
United States200 participantsStarted 2023-01-31
Plain-language summary
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
✓. Age ≥ 18 years at the time of consent.
✓. Subjects suspected of or diagnosed with Stage IV/metastatic NSCLC and meet one of the following criteria:
✓. Subjects who are undiagnosed, have undergone imaging and are suspected to have Stage IV lung cancer.
✓. Subjects with a previous Stage I, II, or III diagnosis of NSCLC, who are being re-biopsied due to suspected progression to metastatic disease.
✓. Subjects who have a newly confirmed diagnosis of Stage IV NSCLC, have undergone a SOC biopsy procedure and will undergo a separate procedure for the purposes of this study prior to starting first line treatment.
✓. Subjects who have a previous Stage IV/metastatic NSCLC diagnosis and have already received first line treatment.
✓. Subjects must be clinically able, at investigator discretion, to undergo additional CNB or forceps biopsy passes during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.
Exclusion criteria
✕. Any patient for whom an extra biopsy might pose a clinical risk based on the discretion of the clinician.
✕. Any mental impairment that would render the patient unable to understand his/her participation in the study would disqualify the patient from consenting and participating.
What they're measuring
1
Sensitivity and Specificity of Cybrid Score for Predicting In-Vivo Clinical Response to Immune Checkpoint Inhibitors
✕. Subjects with an auto-immune disease that would render them ineligible for immune- oncology treatment.
✕. Immunocompromised subjects, and subjects known to be HIV positive and currently receiving antiretroviral therapy. NOTE: Patients known to be HIV positive, but without clinician evidence of an immunocompromised state, are eligible for this trial.
✕. Subjects who are enrolled or plan to be enrolled in a blinded oncology treatment trial are not eligible.